share_log

Oppenheimer Maintains Outperform on Biogen, Maintains $270 Price Target

Benzinga ·  Apr 29 12:49

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and maintains $270 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment